Slide 1: Realising our vision to improve a billion lives
hudrix” Realising our vision to improve a billion lives through disruptive medical devices
Slide 2: Our vision is to improve a billion lives
Hydrix is a fast emerging global diversified medical technology Hydrix Medical Hydrix Ventures company. Bringing to market disruptive Investing in early stage, high cardiovascular products that potential, medical device Our vision is to improve solve unmet needs companies a billion lives To create l
Slide 3: Potential 5x – 10x uplift on cash
• FY22 revenue $10.3m up 40% YoY, ~60 employees • FY22 revenue source: +50% international, +40% cardiovascular technology clients Strong year-on-year growth, Hydrix Services • +$60m sales pipeline, order book value at start of year $12m (~2x pcp) profitability ahead • Trend revenue growth outlook fo
Slide 4: Hydrix Services, Hydrix Medical, Hydrix Ventures
Hydrix Services • Revenue growth & improving margins trending to profitability in FY23 • Q3 CY22: Finalised Australia clinical trial registry Site Initiation o National cardiology group has commenced screening suitable patients for first Australian implants to support commercial market launch • Pend
Slide 5: Targets the $2.1B global outsourced medtech product development sector
Targets the $2.1B global outsourced medtech product development sector Sustained significant growth for FY23 to follow FY22 YoY revenue growth of ~40% International revenues More than 40% of • Qualified sales pipeline +$60m over 50% as a result of revenues relate to • FY23 trend revenue +20% increas
Slide 6: Hydrix selectively makes early-stage venture investments in high potential clients
Hydrix selectively makes early-stage venture investments in high potential clients who leverage our breakthrough product development, regulatory and project management expertise Angel Medical Systems Gyder Surgical Cyban Limited Memphasys USA Limited Limited Developing novel medical devices, Develop
Slide 7: Cardiovascular disease leading cause of death globally
Product Application Problem addressed Status Potential future market uptake & revenue p.a. The World Health Organisation (WHO) AngelMed - The GUARDIAN is a heart attack warning Exclusive rights to distribute identifies Cardiovascular Diseases system that reduces the stresses of living in (8 countrie
Slide 8: The GUARDIAN
The AngelMed GUARDIAN is at the forefront of real-time emergency cardiac event monitoring. The GUARDIAN® It is the world's only FDA approved implantable cardiac Real-time heart attack monitoring monitor with Acute Coronary Syndrome (ACS) detection and detection technology. It is implanted in a manne
Slide 9: Key priorities towards commercial market launch in Australia & Asia Pacific
Hydrix is actively working with the Australian Therapeutic Goods Administration (TGA) and other regulatory bodies to finalise approvals and reimbursement pathways to commence commercial implant journey. Key priorities towards commercial market launch in Australia & Asia Pacific* CY2022 CY2023 Q1 Q2
Slide 10: Australian Addressable Market
The GUARDIAN The world's only FDA approved implantable cardiac monitor with Acute Coronary Syndrome (ACS) detection technology Acute Coronary Syndrome Australian Market Australian Incidences p.a. 75,000 Coronary Heart Disease is Australia’s leading cause of death (17,700). Addressable Key data: Mark
Slide 11: GUARDIAN market penetration leverages pacemaker surgery know-how
GUARDIAN® market penetration leverages >5-decades of pacemaker surgery know-how and existing catheter laboratory infrastructure Potential Market Size (illustration only) Annual Sales Volume (units) Annual Sales Value (A$)2 Region Population (M) ACS Incidences p.a. 1 2.0% 5.0% 2.0% 5.0% Australia 25.
Slide 12: 1 for 2 pro-rata accelerated non-renounceable entitlement offer to raise approximately A$6.0 million
Entitlement Offer size and structure 1 for 2 pro-rata accelerated non-renounceable entitlement offer to raise approximately A$6.0 million (Entitlement Offer). Approximately 98.8 million fully paid ordinary Hydrix shares (New Shares) to be issued under the Entitlement Offer. Baker Young is acti
Slide 13: Entitlement Offer timetable
Event Date (2022) Announcement of the Entitlement Offer and Institutional Entitlement Offer open Thursday, 15 September Hydrix conducts Institutional Entitlement Offer Thursday 15 September – Friday 16 September Announcement of results of Institutional Offer Monday 19 September Trading in Hydrix sha
Slide 14: Risks specific to the Entitlement Offer
Risks specific to the Entitlement Offer Future funding The funds raised by the Entitlement Offer will be applied towards the Company’s working capital requirements, and execution of its buy, build and invest growth strategy. The Company may be required to raise further funds for future operational
Slide 15: Regulatory approvals risk
Regulatory approvals Hydrix Medical Pty Ltd (Hydrix Medical) owns the exclusive rights to distribute Angel Medical Systems, Inc.’s (AngelMed) Guardian® System (Guardian Device) in a required to market the number of Asia Pacific countries (each a Relevant Jurisdiction). The manufacture, labelling,
Slide 16: Reliance on systems and intellectual property risks
Reliance on Systems The successful operation of Hydrix’s business is dependent on various technologies including the internet and dedicated servers. Any significant disruption to these systems could have a materially detrimental effect on Hydrix’s business. Intellectual Property The Company’s co
Slide 17: General risks
General risks Economic risks The operating and financial performance of the Company is influenced by a variety of general economic and business conditions, including levels of consumer spending, inflation, interest rates, access to debt and capital markets, international economic conditions, signi
Slide 18: International offer restrictions: New Zealand, Malaysia
This Information Booklet has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act"). The New Shares are not being offered to the public within New Zealand other than to existing Shareholders of the Company with
Slide 19: International offer restrictions: United Kingdom
Neither this document nor any document relating to the Entitlement Offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000 as amended (“FSMA”)) has been published
Slide 20: Board of Directors
Mr Gavin Coote Mr Paul Wright Mr Paul Lewis Ms Julie King Ms Joanne Bryant Ms Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Corporate Counsel Gavin has extensive executive Paul has spent the last 18 years Paul started his care
Slide 21: Management team
Vickie Edwards Paul Kelly Robert Brierly Alan Morris Mark Langham Director Sales & General Manager, Global Director, Group Marketing Director Group Financial Controller Operations, Hydrix Hydrix Medical Human Resources Medical Vickie has more than 25 years’ of Vickie has more than 25 years’ of A pas
Slide 22: Hydrix Services management team
Michael Trieu Peter Riddell Graeme Robertson Andrew Beal Peter Lewis, AM General Manager Director Business Project Management Engineering Manager EVP Business Development Hydrix Services Development Office Director Hydrix Services Hydrix Services Hydrix Services Hydrix Services Michael is an R&D Pet
Slide 23: Major shareholders, capital structure and share price history
Major Shareholders Shares (m) % Capital Structure (as of 4 September 2022) John W. King Nominees 21.4 10.8 Ticker HYD Patagorang & related entities (Roger Allen) 10.4 5.3 Share Price $0.091 Invia Custodian (Paul Lewis) 9.9 5.0 Shares on Issue (m) 197.6 Pusen Medical Technology Australia Pty Ltd 6.6
Slide 24: Diversified global medtech company – 20 year history in breakthrough product development
• Diversified global medtech company – 20 year history in breakthrough product development, Melbourne-based, 70 employees • Commercial model consists of three complementary business segments: • Services: Internationally recognised and awarded fee-for-service product design and engineering business o
Slide 25: www.hydrix.com
hudrix™ www. hydrix.com
Slide 26: Important notice: not an offer document
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES This presentation is dated 15 September 2022 and has been prepared and authorised by Hydrix Limited (ACN 060 369 048) (“Hydrix”) in connection with an accelerated pro-rata non-renounceable entitlement offer of fully paid ordinary shares (New Share
Slide 27: Forward looking statements
FORWARD LOOKING STATEMENTS The information in this presentation is subject to change without notice and Hydrix is not obliged to update or correct it. This presentation contains statements that constitute "forward looking statements". The forward looking statements include statements regarding Hydri